[go: up one dir, main page]

EE03955B1 - Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks - Google Patents

Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks

Info

Publication number
EE03955B1
EE03955B1 EE9700133A EE9700133A EE03955B1 EE 03955 B1 EE03955 B1 EE 03955B1 EE 9700133 A EE9700133 A EE 9700133A EE 9700133 A EE9700133 A EE 9700133A EE 03955 B1 EE03955 B1 EE 03955B1
Authority
EE
Estonia
Prior art keywords
cells
nucleic acid
transfecting
medicament
manufacture
Prior art date
Application number
EE9700133A
Other languages
English (en)
Other versions
EE9700133A (et
Inventor
Stephen Charnock-Jones David
Kevin Smith Stephen
Mark Sharkey Andrew
Brian Heap Robert
Original Assignee
Cambridge University Technical Services Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426380.3A external-priority patent/GB9426380D0/en
Application filed by Cambridge University Technical Services Limited filed Critical Cambridge University Technical Services Limited
Publication of EE9700133A publication Critical patent/EE9700133A/et
Publication of EE03955B1 publication Critical patent/EE03955B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
EE9700133A 1994-12-24 1995-12-21 Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks EE03955B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9426380.3A GB9426380D0 (en) 1994-12-24 1994-12-24 Regulation of endometrial function by in vivo gene transfer
GBGB9520879.9A GB9520879D0 (en) 1994-12-24 1995-10-12 Improvements in or relating to endometrial function
PCT/GB1995/003008 WO1996020013A1 (en) 1994-12-24 1995-12-21 Improvements in or relating to endometrial function

Publications (2)

Publication Number Publication Date
EE9700133A EE9700133A (et) 1997-12-15
EE03955B1 true EE03955B1 (et) 2003-02-17

Family

ID=26306279

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700133A EE03955B1 (et) 1994-12-24 1995-12-21 Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks

Country Status (23)

Country Link
US (2) US6472374B1 (et)
EP (1) EP0799058B1 (et)
JP (2) JPH10511548A (et)
KR (1) KR20050052548A (et)
CN (1) CN1241646C (et)
AT (1) ATE234637T1 (et)
AU (1) AU712278B2 (et)
BG (1) BG63332B1 (et)
BR (1) BR9510408A (et)
CA (1) CA2208446A1 (et)
CZ (1) CZ293770B6 (et)
DE (1) DE69530001T2 (et)
DK (1) DK0799058T3 (et)
EE (1) EE03955B1 (et)
ES (1) ES2323909T3 (et)
HU (1) HU221204B1 (et)
MX (1) MX9704765A (et)
NO (1) NO320436B1 (et)
NZ (1) NZ297537A (et)
PL (1) PL192784B1 (et)
PT (1) PT799058E (et)
SK (1) SK284119B6 (et)
WO (1) WO1996020013A1 (et)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778737B2 (en) 1999-04-14 2004-12-16 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6777639B2 (en) 2002-06-12 2004-08-17 Nanotechnologies, Inc. Radial pulsed arc discharge gun for synthesizing nanopowders
US7704965B2 (en) 2002-06-26 2010-04-27 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
US7012214B2 (en) * 2003-09-24 2006-03-14 Nanotechnologies, Inc. Nanopowder synthesis using pulsed arc discharge and applied magnetic field
WO2005047483A2 (en) 2003-11-12 2005-05-26 Medical Research Council Renta: an hiv immunogen and uses thereof
CA2654324A1 (en) 2006-06-02 2007-12-13 International Aids Vaccine Initiative Hiv-1 clade a consensus sequences, antigens, and transgenes
US20080050814A1 (en) * 2006-06-05 2008-02-28 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of fetal placental cells
WO2007146105A2 (en) * 2006-06-05 2007-12-21 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of fetal placental cells
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
AP2013007180A0 (en) 2011-04-25 2013-10-31 Advanced Bioscience Lab Inc Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
ES2807173T3 (es) 2012-09-10 2021-02-22 Int Aids Vaccine Initiative Inmunógenos de anticuerpos ampliamente neutralizantes del VIH-1, métodos de generación y usos de los mismos
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
KR101802090B1 (ko) 2016-09-26 2017-11-27 서울대학교산학협력단 탈락막 자궁내막 세포를 포함하는 자궁내막 손상의 치료용 조성물
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
EP4106809A1 (en) 2020-02-21 2022-12-28 International AIDS Vaccine Initiative, Inc. Vaccine compositions for preventing coronavirus disease
CN112458161A (zh) * 2020-11-12 2021-03-09 深圳市锦欣医疗科技创新中心有限公司 一组子宫内膜容受性生物标志物、试剂盒及判断子宫内膜容受性的方法
KR20220083029A (ko) * 2020-12-11 2022-06-20 주식회사 커스토젠 자궁내막 비후용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1994005782A1 (en) * 1992-09-10 1994-03-17 Trustees Of Tufts College In vivo production of transgenic organ by introducing the transgene via lumen
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors

Also Published As

Publication number Publication date
AU4270796A (en) 1996-07-19
CZ293770B6 (cs) 2004-07-14
MX9704765A (es) 1998-02-28
CN1174508A (zh) 1998-02-25
CA2208446A1 (en) 1996-07-04
HUT77338A (hu) 1998-03-30
NZ297537A (en) 2000-04-28
PT799058E (pt) 2003-11-28
DE69530001T2 (de) 2004-06-03
BG63332B1 (bg) 2001-10-31
BR9510408A (pt) 1998-11-10
EE9700133A (et) 1997-12-15
PL324088A1 (en) 1998-05-11
DK0799058T3 (da) 2003-11-24
US20030186907A1 (en) 2003-10-02
BG101714A (en) 1998-03-31
US6472374B1 (en) 2002-10-29
AU712278B2 (en) 1999-11-04
NO972935L (no) 1997-08-22
SK80197A3 (en) 1998-04-08
PL192784B1 (pl) 2006-12-29
ATE234637T1 (de) 2003-04-15
NO972935D0 (no) 1997-06-23
CN1241646C (zh) 2006-02-15
DE69530001D1 (de) 2003-04-24
WO1996020013A1 (en) 1996-07-04
KR20050052548A (ko) 2005-06-02
EP0799058B1 (en) 2003-03-19
JP2006124402A (ja) 2006-05-18
CZ191797A3 (cs) 1998-06-17
SK284119B6 (sk) 2004-09-08
JPH10511548A (ja) 1998-11-10
NO320436B1 (no) 2005-12-05
ES2323909T3 (es) 2009-07-27
EP0799058A1 (en) 1997-10-08
HU221204B1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
EE03955B1 (et) Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
DE69019009D1 (de) Zellkulturverfahren.
FI894888A7 (fi) Astaksantiinia tuottavia hiivasoluja, menetelmiä niiden valmistamiseks i ja niiden käyttö
YU47800B (sr) Estri tienil-karboksilne kiseline sa aminoalkoholima, njihova kvaterna jedinjenja kao i pripremanje tih jedinjenja
DE3585542D1 (de) Methoden zur herstellung biologisch aktiver membranen und ihre verwendungen.
IT8319597A0 (it) Estrattori per composizioni alcossi-funzionali ad un componente, vulcanizzabili atemperatura ambiente e procedimenti per fare i medesimi.
DE68901782D1 (de) Brennstoffzelle, elektrode fuer die zelle und verfahren zur herstellung.
DE3580283D1 (de) Biologisch wirksame substanz mit hormonellen eigenschaften, verfahren zu ihrer herstellung und verwendung von histonen fuer medizinische zwecke.
CA2058930A1 (en) Media for cell growth and method for making them
IE830945L (en) Process for obtaining permanently culturable animal and¹human cell lines
DE3583170D1 (de) Elektrode fuer brennstoffzelle, verfahren zu ihrer herstellung und diese elektrode verwendende brennstoffzelle.
DE2967701D1 (de) A-21978 genannte antibiotische mischung, verfahren zu ihrer herstellung, ihre pharmazeutischen zusammensetzungen und produzierender mikroorganismus.
DE3483427D1 (de) Bei niedriger temperature durch erwaermung schrumpfbarer film und dessen herstellung.
DE69007361D1 (de) Festoxidbrennstoffzelle und Verfahren zu ihrer Herstellung.
DE3888887D1 (de) Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
DE69012168D1 (de) Nichtwässerige elektrochemische Zelle und Verfahren zu ihrer Herstellung.
DE3862788D1 (de) Fluessige oxydationsmodifizierte ethylenische statistische copolymere, verfahren zur herstellung und deren verwendung.
DE3584839D1 (de) Zubereitung fuer die zellkultur, ihre herstellung und verwendung.
ES2047946T3 (es) Metodos de cultivos celulares para producir proteina c activada.
ATE34386T1 (de) 1,2,3,4-tetrahydro-1-aminomethyl-4-phenylisochinoline und verfahren zu ihrer herstellung.
AR240829A2 (es) Procedimiento para aislar levamisol de tetramisol
JPS5411233A (en) Anitidote
DE3675631D1 (de) In-vitro-kulturverfahren.
DE3583601D1 (de) Plasmid, verfahren zu dessen herstellung, dieses plasmid enthaltender mikroorganismus und verfahren zur zuechtung des mikroorganismus.
JPS56152496A (en) Novel o-side derivative having blood type properties,manufacture thereof and biological application thereof

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20081221